Compounds > 6,15-diketo-13,14-dihydroprostaglandin f1alpha
Page last updated: 2024-09-05

6,15-diketo-13,14-dihydroprostaglandin f1alpha and thromboxane b2

6,15-diketo-13,14-dihydroprostaglandin f1alpha has been researched along with thromboxane b2 in 1 studies

Compound Research Comparison

Studies
(6,15-diketo-13,14-dihydroprostaglandin f1alpha)		Trials
(6,15-diketo-13,14-dihydroprostaglandin f1alpha)		Recent Studies (post-2010)
(6,15-diketo-13,14-dihydroprostaglandin f1alpha)		Studies
(thromboxane b2)		Trials
(thromboxane b2)		Recent Studies (post-2010) (thromboxane b2)
11007,483715485

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cato, AE; Crow, JW; Danviriyasup, K; Dunn, MJ; Hassid, A; Park, GD; Smith, MC1

Other Studies

1 other study(ies) available for 6,15-diketo-13,14-dihydroprostaglandin f1alpha and thromboxane b2

ArticleYear
Prostacyclin substitution for heparin in long-term hemodialysis.
    The American journal of medicine, 1982, Volume: 73, Issue:5

    Topics: 6-Ketoprostaglandin F1 alpha; Adult; Anticoagulants; Epoprostenol; Female; Heparin; Humans; Kidney Failure, Chronic; Male; Middle Aged; Platelet Aggregation; Prostaglandins; Radioimmunoassay; Renal Dialysis; Thromboxane B2

1982